Apellis Pharmaceuticals is a startup based in the United States, most recent round Series-c-plus.
Based in the United States, Apellis Pharmaceuticals is a startup. Its most recent tracked round is Series-c-plus.
Apellis Pharmaceuticals is a biopharmaceutical company developing therapies that inhibit the complement system; its lead program, pegcetacoplan, is being developed for retinal disease (geographic atrophy) and other complement-mediated disorders.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.